Insights
Thinking on UK and Irish market access for early-stage medtech, the structural patterns that produce success and failure, and how the data and AI layers are changing what is possible at this price point. New writing posted approximately once a quarter.
Designing a productised market access firm for the bottom of the pyramid
The argument behind the firm. Why the £15–60k segment is structurally underserved, what changes when methodology, evidence and AI are productised rather than bespoke per engagement, and how this changes the economics of what an early-stage medtech can afford to buy. Co-authored with James Barlow.
The year-2 cliff: why pilots stall and what to do about it
A working draft, building on the cliff methodology developed for the Phyxiom engagement. The post-pilot retention failure is the single most common reason promising health-tech companies stall in the NHS. We argue it is structural rather than commercial, and outline what a Phase 4 retainer relationship actually does.
The State of Health-Tech Adoption
An annual industry report co-authored with James Barlow at Imperial and a small number of named industry partners. A view of where the UK and Irish health-tech ecosystem is in adoption terms, and where the binding constraints sit.
Subscribe to the quarterly note
A short quarterly note from the firm — one substantive piece of writing plus a brief round-up of what has shifted in the NHS market-access landscape since the last edition. To be added to the distribution list, email hello@strategiapathway.co.uk.